Araújo Diana, Cabral Inês, Vale Nuno, Amorim Irina
Institute of Biomedical Sciences Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
Fitzpatrick Referrals Oncology and Soft Tissue, 70 Priestley Rd, Guildford GU2 7AJ, UK.
Vet Sci. 2022 Jul 26;9(8):383. doi: 10.3390/vetsci9080383.
Human gastric cancer (GC) ranks as the fifth most prevalent cancer worldwide, and is the third leading cause of cancer-related death. The incidence of GC is lower in dogs than in humans, accounting for less than 1% of all canine malignancies. In recent years, efforts have been made to understand the pathogenesis of GC and in find an appropriate therapy to maximize curative results, such as adjuvant chemotherapy treatments in addition to surgery. Although surgery is the first-line treatment, it is associated with several complications. In terms of chemotherapeutic intervention, canine gastric cancer has not received much attention, probably due to its late diagnosis, fast progression, low median survival time, and very high mortality rate, along with the lack of publications with concrete scientific results. In this review, we explore canine GC and the pharmacological approach used in the treatment of this often-fatal disease.
人类胃癌(GC)是全球第五大常见癌症,也是癌症相关死亡的第三大主要原因。犬类胃癌的发病率低于人类,占所有犬类恶性肿瘤的比例不到1%。近年来,人们一直在努力了解胃癌的发病机制,并寻找合适的治疗方法以实现最佳治疗效果,例如除手术外还进行辅助化疗。虽然手术是一线治疗方法,但它会引发多种并发症。在化疗干预方面,犬类胃癌并未受到太多关注,这可能是由于其诊断较晚、进展迅速、中位生存时间短、死亡率极高,以及缺乏有具体科学成果的出版物。在本综述中,我们探讨犬类胃癌以及用于治疗这种常致命疾病的药理学方法。